X4 Pharmaceuticals to Participate in Stifel’s Virtual Healthcare Conference
X4 Pharmaceuticals (Nasdaq: XFOR) announced its participation in the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 11:20 AM ET. The event will feature a fireside chat, which will be available via live webcast on X4's investor website. X4 is focused on developing novel CXCR4-targeted therapies for immune system diseases, with mavorixafor as its lead candidate. The company is advancing mavorixafor through various clinical trials for conditions including primary immunodeficiencies and certain cancers. The archived event will be accessible for 90 days post-conference.
- None.
- None.
BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today announced that management will participate in a fireside chat at Stifel’s Virtual Healthcare Conference on Wednesday, November 17, 2021.
Details are as follows:
Conference: Stifel 2021 Virtual Healthcare Conference
Date: Wednesday, November 17, 2021
Time: 11:20 AM ET
Fireside Chat Webcast Link
A live webcast of the fireside chat from the Stifel 2021 Virtual Healthcare Conference will be available on the investors section of the X4 Pharmaceuticals’ website at www.x4pharma.com. After the live webcast, the event will remain archived on the X4 Pharmaceuticals’ website for approximately 90 days.
About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company leading the discovery and development of novel therapies for people with diseases of the immune system. The company’s lead candidate is mavorixafor, a first-in-class, small molecule antagonist of chemokine receptor CXCR4 that is being developed as a once-daily oral therapy. Due to mavorixafor’s ability to antagonize CXCR4 and improve the healthy maturation and trafficking of white blood cells, X4 believes that mavorixafor has the potential to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies (PIDs) and certain types of cancer. Mavorixafor has already demonstrated clinical potential in a Phase 2 trial in people with WHIM syndrome, a rare PID. Its efficacy and safety continue to be evaluated in a global Phase 3 clinical trial in WHIM (fully enrolled) and in two Phase 1b clinical trials – one, as monotherapy in people with Severe Congenital Neutropenia (SCN) and other chronic neutropenia conditions, and another in combination with ibrutinib in people with Waldenström’s macroglobulinemia. X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, to discover and develop additional product candidates. For more information, please visit www.x4pharma.com.
Investors and Media:
Daniel Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
Mónica Rouco Molina
Senior Account Executive
LifeSci Communications
mroucomolina@lifescicomms.com
FAQ
When is X4 Pharmaceuticals participating in the Stifel 2021 Virtual Healthcare Conference?
How can I watch the X4 Pharmaceuticals fireside chat?
What is the focus of X4 Pharmaceuticals?
What is mavorixafor and what is its significance?
Are there any ongoing clinical trials for mavorixafor?
